The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – PED-CITN-03
Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma
Cancer Immunotherapy Trials Network
Majzner, Robbie G.
(650) 723-5535
Phase II – ACNS2021
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Children’s Oncology Group
MacDonald, Shannon Michelle
(617) 726-5184
Phase II – EA2192
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
ECOG-ACRIN Cancer Research Group
Reiss Binder, Kim Anna
(215) 360-0735
Phase II – EA2201
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
ECOG-ACRIN Cancer Research Group
Ciombor, Kristen Keon
(615) 936-8422
Phase II – NRG-GY023
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
NRG Oncology
Lee, Jung-min
(301) 443-7735
Phase II – PBTC-058
Phase 2 Study of Intraventricular Omburtamab-Based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Karajannis, Matthias A.
(212) 639-3171
Phase III – NRG-BR007
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer (DEBRA)
NRG Oncology
White, Julia R.
(614) 688-7367
Phase Other – S2013
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
SWOG
Gunturu, Krishna Soujanya
(781) 744-8400
